PGNY

Rating neutralAI MemoPost-earnings T+1

Progyny

As of 2026-05-08/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 print de-risked the February reset and lifted the 2026 revenue floor • 2026-05-08

Expected move: -23%

Biggest risk

This is still not a clean all-clear. Reported revenue growth was only 1.4% because the lost large client remains a difficult comparison, adjusted EBITDA margin fell to 17.2% from 17.8% as the company continued platform and member-experience investments, and management still framed guidance around a range of member engagement outcomes plus macro uncertainty. T+1 analyst revision breadth was not available in the packet, so conviction should not be upgraded too aggressively from one print.

Invalidation

Break below $18 or thesis failure.

What would change my mind?

The post-earnings read is better than the pre-print setup: Q1 revenue landed near the high end of the company’s prior range, reported growth was 12.2% excluding the lapsed large client, gross margin expanded to 25.3%, and the full-year revenue range was tightened upward at the low end. The stock’s move from the May 7, 2026 close of $19.16 to about $23.45 on May 8, 2026 indicates the market viewed the print as a meaningful relief event.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$25

p=45%

Bull target

$30

p=30%

Bear target

$18

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Board decision on a new repurchase authorization is a near-term support watchpoint
2026 client launches and selling-season traction need to convert into cleaner reported growth
The post-earnings read is better than the pre-print setup: Q1 revenue landed near the high end of the company’s prior range, reported growth was 12.2% excluding the lapsed large client, gross margin expanded to 25.3%, and the full-year revenue range was tightened upward at the low end.

BearKey bullets

Adjusted EBITDA margin declined year over year as Progyny continued planned investments in platform features and member experience, so growth may not translate one-for-one into incremental profit if spending stays elevated [#8-K-2026-05-07].
After the sharp T+1 rally, execution expectations are higher; any miss on Q2 launches, utilization, or selling-season conversion could retrace part of the move.
Member utilization and engagement remain the core swing factor; management explicitly kept guidance as a range because utilization can vary and macroeconomic uncertainty could affect demand [#8-K-2026-05-07].

WatchKey bullets

Q1 print de-risked the February reset and lifted the 2026 revenue floor

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $25 (p=45%)

Bull/Bear spread: -7% / -44%

Vs latest close: Bull -7% · Base -23% · Bear -44%

Scenario probabilities

Bull Target: $30 (p=30%)Base Target: $25 (p=45%)Bear Target: $18 (p=25%)

Commentary

Headline tone improved materially on May 7-8, 2026 because the company paired a solid Q1 report with a modest upward revision to the full-year revenue floor, and the stock rallied about 22.4% on May 8 versus the May 7 close. That said, this is still an early T+1 follow-up run: immediate analyst target and estimate revisions were not available in the packet, so the reaction looks more like relief plus guidance stabilization than a fully digested re-rating. Social coverage was not provided, so monitoring should stay anchored to filings and subsequent revision data rather than narrative momentum.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Board decision on a new repurchase authorization is a near-term support watchpoint
2026 client launches and selling-season traction need to convert into cleaner reported growth

Scenarios

Bull Target (Scenario probability)

$30 / p=30% prob

Base Target (Scenario probability)

$25 / p=45% prob

Bear Target (Scenario probability)

$18 / p=25% prob

Price $32 as of 2026-07-14

Nearest Scenario: Bull (∆ 7%)

Targets vs latest close: Bull -7% · Base -23% · Bear -44%

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-08
Q1 print de-risked the February reset and lifted the 2026 revenue floor
Progyny reported record Q1 2026 revenue of $328.5 million, gross margin of 25.3%, net income of $24.2 million, and said there was no contribution from the previously disclosed non-renewed large client in the quarter; it also raised the low end of full-year 2026 revenue guidance to $1.365 billion from $1.355 billion while keeping the high end at $1.405 billion [#8-K-2026-05-07].
Prob 85.00% • Move 12.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Board decision on a new repurchase authorization is a near-term support watchpoint
2026-05-31
The company completed its November 2025 $200 million repurchase authorization by March 31, 2026 after buying 8.8 million shares cumulatively, and management said the board was evaluating options for a new program with an announcement anticipated around the end of May; that can matter for support after the post-earnings rebound [#8-K-2026-05-07][#10-Q-2026-05-08].
Prob 60% • Move 8% • Priced-in 45%

Long-term Catalysts

Months to a year

2026 client launches and selling-season traction need to convert into cleaner reported growth
2026-12-31
Management said most recent selling-season wins went live in Q1, a handful of additional clients are expected to launch in Q2, and the company continues to expect more than 600 clients and about 7.2 million covered lives once all 2026 launches are live; if that demand converts without another utilization or client-mix disappointment, the growth narrative can improve through 2026 [#8-K-2026-05-07][#10-Q-2026-05-08].
Prob 58% • Move 16% • Priced-in 40%

Risks

Adjusted EBITDA margin declined year over year as Progyny continued planned investments in platform features and member experience, so growth may not translate one-for-one into incremental profit if spending stays elevated [#8-K-2026-05-07].
After the sharp T+1 rally, execution expectations are higher; any miss on Q2 launches, utilization, or selling-season conversion could retrace part of the move.
Member utilization and engagement remain the core swing factor; management explicitly kept guidance as a range because utilization can vary and macroeconomic uncertainty could affect demand [#8-K-2026-05-07].
Regulatory and legal changes affecting fertility benefits, abortion-related care, healthcare spending, or employer benefits design could reduce adoption or limit covered services over time [#10-Q-2026-05-08].
The company still has meaningful exposure to client budgets, workforce levels, and the technology sector; the 10-Q says no client was above 10% of Q1 2026 revenue, but large-client churn has already been a recent earnings headwind [#10-Q-2026-05-08].

Peers

Symbol	Summary
ENOV	Same-sector market-cap peer from the packet, but not a close operating comp to fertility and women’s-health benefits administration; useful mainly as a loose small/mid-cap healthcare valuation reference.
ATRC	Another packet-supplied small/mid-cap healthcare services-device adjacent name rather than a direct business-model peer, reinforcing that relative-value readthrough is limited and the memo should stay monitoring-oriented.
ABT	Large diversified healthcare benchmark, not a direct comparable for PGNY’s employer-benefits model; only useful as a broad sector sentiment anchor, not for operating multiple precision.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: PGNY - Progyny - RankAlpha